Skip to Content



On your first day as a Cardiovascular Surgeon, Ethicon was there. It is the mission of Ethicon to be a valuable partner at every step of CV surgical procedures. Surgeons know that for decades Ethicon has been committed to CV surgery.

Our CV Sutures and DERMABOND ADVANCED™ Topical Skin Adhesive are considered the standard of care in operating rooms around the world and are requested by more surgeons than any other brand.

Ethicon Biosurgery develops products that aid in achieving hemostasis at complex surgical sites during cardiovascular procedures. Products like the SURGICEL® Family of Absorbable Hemostats and EVICEL™ Fibrin Sealant (Human) serve as an adjunct to hemostasis when control of bleeding by standard surgical techniques is ineffective or impractical.

Explore the links to the left to learn more about our specific products and solutions that we offer within individual medical areas.

EVICEL™ Fibrin Sealant (Human)


EVICEL® Fibrin Sealant (Human) is indicated as an adjunct to hemostasis for use in patients undergoing surgery, when control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical.

Important Safety Information:

For topical use only. Do not inject directly into the circulatory system.

Not indicated for the treatment of severe or brisk arterial bleeding.

Do not use in individuals known to have anaphylactic or severe systemic reaction to human blood products.

Air or gas embolism has occurred with the use of spray devices employing pressure regulator to administer fibrin sealants. These events appear to be related to the use of the spray device at higher than recommended pressures and in close proximity to the surface of the tissue. Follow labeled application instructions regarding pressure range and distance when using a spray device and monitor patients for the possibility of air or gas embolism.

Because this product is made from human plasma it may carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Anaphylactic reactions may occur.

Most common adverse events reported in clinical trials (≥5%) are bradycardia, nausea, hypokalemia, insomnia, hypotension, pyrexia, graft infection, vascular graft occlusion, oedema peripheral, constipation.

See sales representative for Full Prescribing Information


Distributed by:
Johnson & Johnson Wound Management
P.O. Box 151, Somervile, NJ 08876-0151

Manufactured by:
OMRIX biopharmaceuticals Ltd.
MDA Blood Bank,
Sheba Hospital, Ramar-Gan
POB 888, Kiryat Ono 55000